Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LTGO

Latigo Biotherapeutics Inc

22.37

Aug 21 • 3:59 PM ET +0.97 (4.53%)

22.70

Aftermarket • 7:30 PM ET +0.33 (1.48%)

Healthcare Biotechnology USA Small NASD

Index	-
Market Cap	1.41B
Enterprise Value	1.66B
Income	-
Sales	-
Book/sh	-3.99
Cash/sh	0.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	33.39
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.23
Current Ratio	3.23
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	76.22%
Insider Trans	0.58%
Inst Own	15.41%
Inst Trans	7.66%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.74%
SMA50	12.74%
SMA200	12.74%
Trades

Shs Outstand	63.24M
Shs Float	15.04M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	22.47 -0.45%
52W Low	17.22 29.91%
Volatility	6.20% -
ATR (14)	1.55
RSI (14)	-
Beta	-
Rel Volume	0.35
Avg Volume	561.10K
Volume	197,197

Perf Week	14.78%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	6.52%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	21.40
Price	22.37
Change %	4.53%

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

CEOMr. Nima Farzan M.B.A.

Chief Business Officer & CFOMs. Neha Krishnamohan

Chief Medical OfficerDr. Neil Kumar Singla M.D.

Senior Vice President of OperationsMs. Julia Chapman

Vice President of Corporate DevelopmentMs. Caroline Dougherty

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Capital Management V,	10% Owner	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:21 PM
Tananbaum James B.	Director	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:00 PM

Open in Screener

ALMS

Alumis Inc

24.17

Aug 21 • 3:59 PM ET +1.31 (5.73%)

23.83

Aftermarket • 7:30 PM ET -0.34 (-1.41%)

Healthcare Biotechnology USA Mid NASD

Peers: CGON ERAS TNGX KYMR BMRN CRNX INCY APGE KRYS RYTM

| Held by: VTI IWM VXF IWO IBB VTWO XPH SCHA IHE VHT

Index	RUT
Market Cap	3.23B
Enterprise Value	2.76B
Income	-438.96M
Sales	7.40M
Book/sh	3.52
Cash/sh	3.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	224
IPO	Jun 28, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	436.02
P/B	6.87
P/C	6.42
P/FCF	-
EV/EBITDA	-
EV/Sales	373.07
Quick Ratio	6.74
Current Ratio	6.74
Debt/Eq	0.08
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	-3.81
EPS next Y	-2.80
EPS next Q	-0.75
EPS this Y	-13.78%
EPS next Y	14.00%
EPS next 5Y	11.23%
EPS past 3/5Y	-9.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	15.36%
Sales Y/Y TTM	-63.11%
EPS Q/Q	-243.88%
Sales Q/Q	-37.66%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-44.88% -54.49%

Insider Own	27.87%
Insider Trans	-0.05%
Inst Own	65.92%
Inst Trans	3.30%
ROA	-74.94%
ROE	-93.65%
ROIC	-90.74%
Gross Margin	52.31%
Oper. Margin	-5479.55%
Profit Margin	-5933.45%
SMA20	-7.58%
SMA50	-8.57%
SMA200	12.16%
Trades

Shs Outstand	124.45M
Shs Float	96.29M
Short Float	5.99%
Short Ratio	4.45
Short Interest	5.77M
52W High	31.35 -22.90%
52W Low	3.76 542.82%
Volatility	7.17% 7.05%
ATR (14)	1.82
RSI (14)	42.39
Beta	-0.73
Rel Volume	0.72
Avg Volume	1.30M
Volume	934,814

Perf Week	-4.50%
Perf Month	-14.59%
Perf Quarter	9.02%
Perf Half Y	-13.59%
Perf YTD	147.64%
Perf Year	425.43%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.30
Target Price	40.33
Prev Close	22.86
Price	24.17
Change %	5.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Downgrade	H.C. Wainwright	Buy → Neutral	$25
Mar-11-26	Initiated	Raymond James	Strong Buy	$46
Feb-25-26	Initiated	Stifel	Buy	$44
Jan-21-26	Initiated	Chardan Capital Markets	Buy	$37
Jul-25-25	Initiated	Wells Fargo	Overweight	$17
Jun-10-25	Resumed	Guggenheim	Buy	$18
Jan-30-25	Initiated	Oppenheimer	Outperform	$32
Oct-31-24	Initiated	Robert W. Baird	Outperform	$25
Oct-17-24	Initiated	H.C. Wainwright	Buy	$30
Jul-23-24	Initiated	Morgan Stanley	Overweight	$36
Jul-23-24	Initiated	Leerink Partners	Outperform	$29
Jul-23-24	Initiated	Guggenheim	Buy	$32
Jul-23-24	Initiated	Cantor Fitzgerald	Overweight

Show Previous Ratings

Aug-13-26 04:01PM	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Aug-10-26 04:05PM	Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies (GlobeNewswire) -7.85%
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive) -7.15%
May-14-26 04:05PM	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-28-26 01:30PM	Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis (GlobeNewswire)
04:05PM	Loading…
Mar-19-26 04:05PM	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Mar-18-26 08:00AM	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-02-26 08:05AM	Alumis to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-26 08:10PM	Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference (MarketBeat)
Feb-12-26 11:42AM	Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit (MarketBeat)
Feb-05-26 08:05AM	Alumis to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 09:48AM	Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials (Insider Monkey) -8.68%
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
Jan-16-26 08:39PM	Staar Surgical, Alumis, and More Stocks See Action From Activist Investors (Barrons.com) +9.22%
Jan-15-26 04:12PM	David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 (Benzinga)
11:35AM	Loading…
11:35AM	HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating (Insider Monkey)
Jan-09-26 04:05PM	Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +7.59% +7.82%
Jan-08-26 08:56AM	What's Going On With Alumis Stock Thursday? (Benzinga)
Jan-07-26 10:52PM	Alumis Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +10.41%
11:52AM	ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies (Zacks)
11:35AM	Should You Chase the Rally in Alumis Stock Today? (Barchart)
Jan-06-26 05:30PM	Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly Takeover (Investor's Business Daily) +95.31%
04:29PM	Alumis Stock Catapults More Than 95% As Biotech Takes On J&J, Protagonist In Psoriasis (Investor's Business Daily)
04:12PM	Alumis Announces Proposed Public Offering of Common Stock (GlobeNewswire)
10:59AM	Alumis Stock Hits Record High on Psoriasis Drug Trial Results (Schaeffer's Research)
07:00AM	Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program (GlobeNewswire)
Jan-05-26 05:00PM	Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire) -7.20%
Nov-13-25 04:15PM	Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (GlobeNewswire)
Nov-04-25 08:00AM	Alumis to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Aug-29-25 07:00AM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-13-25 04:05PM	Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-25 05:31PM	TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications \| DelveInsight (PR Newswire)
Jul-29-25 10:23AM	Alumis (ALMS) Merges with ACELYRIN (Insider Monkey)
Jul-24-25 07:30AM	Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Jul-14-25 04:05PM	Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary (GlobeNewswire)
May-30-25 05:23AM	Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy (Clinical Trials Arena) -10.49%
May-29-25 04:15PM	Alumis to Present at the Jefferies Global Healthcare Investor Conference (GlobeNewswire)
07:55AM	Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
May-21-25 09:10AM	Alumis Completes Merger with ACELYRIN (GlobeNewswire)
May-14-25 04:05PM	Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements (GlobeNewswire) +18.63%
May-13-25 01:00PM	Alumis Stockholders Approve Merger with ACELYRIN (GlobeNewswire) -15.05%
01:00PM	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire)
May-06-25 04:30PM	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote FOR the Proposed Transaction with Alumis (GlobeNewswire) +10.11%
May-02-25 01:45PM	Acelyrin urges stockholders to vote for proposed merger with Alumis (TipRanks) +19.84%
May-01-25 01:30PM	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis (GlobeNewswire) -7.49%
Apr-29-25 01:22PM	Acelyrin should liquidate instead of merging with Alumis, investor says (BioPharma Dive) +5.10%
Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire) -6.00%
Apr-10-25 07:00AM	3 Biopharmaceutical Stocks Bucking the Sell-Off (MarketBeat) -15.05%
Apr-07-25 01:43PM	Alumis: Biotech's Stock Gains >100% In A Month - But Risk Of Failure Is High (Seeking Alpha)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) +17.68%
Mar-25-25 10:51AM	Alumis and Kaken sign agreement in Japan to develop ESK-001 (Pharmaceutical Technology) +5.96%
02:30AM	Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan (GlobeNewswire)
Mar-21-25 07:08AM	Why Alumis Inc. (ALMS) Went Down On Thursday? (InsiderMonkey) +5.04%
Mar-19-25 04:05PM	Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire) -18.31%
Mar-10-25 08:00AM	Alumis to Present at Leerink's 2025 Global Healthcare Conference (GlobeNewswire)
Mar-08-25 09:00AM	Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis (GlobeNewswire)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
Feb-28-25 09:08AM	Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout (GlobeNewswire)
Feb-27-25 04:15PM	Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases (GlobeNewswire)
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-10-25 04:45PM	Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -14.99%
Feb-07-25 10:44AM	Alumis and Acelyrin sign merger agreement (Pharmaceutical Technology) -13.96%
03:00AM	Immune drugmakers Alumis and Acelyrin to merge (BioPharma Dive)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) -7.57%
Jan-30-25 02:48PM	Why Alumis (ALMS) Stock Is Advancing Today (Insider Monkey)
Jan-28-25 08:00AM	Alumis Strengthens Leadership Team with Key Appointments (GlobeNewswire)
Dec-19-24 08:00AM	Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 (GlobeNewswire)
Nov-14-24 04:05PM	Alumis Presents Data Highlighting ESK-001's Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024 (GlobeNewswire) -12.95% -5.95%
Nov-13-24 04:05PM	Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements (GlobeNewswire)
Nov-04-24 08:00AM	Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-27-24 09:00AM	Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study (GlobeNewswire) -6.77%
Sep-03-24 04:29PM	Alumis to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements (GlobeNewswire)
Jul-29-24 08:00AM	Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis (GlobeNewswire)
Jun-27-24 11:57PM	Alumis Announces Pricing of Initial Public Offering (GlobeNewswire)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

PresidentMr. Martin Babler Ph.D.

Chief Scientific OfficerDr. David M. Goldstein Ph.D.

Ph.D.Dr. Jorn Drappa M.D.

Chief Financial OfficerMr. John R. Schroer C.F.A.

Chief Legal Officer & Corporate SecretaryMs. Sanam Pangali J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schroer John R.	Chief Financial Officer	Aug 03 '26	Sale	26.37	3,282	86,546	24,718	Aug 05 06:50 PM
Pangali Sanam	Chief Legal Officer	Aug 03 '26	Sale	26.37	1,364	35,969	9,747	Aug 05 06:46 PM
Hardiman Roy C.	Chief Business & Strategy Ofcr	Aug 03 '26	Sale	26.37	2,692	70,988	207,746	Aug 05 06:44 PM
Goldstein David M	Chief Scientific Officer	Aug 03 '26	Sale	26.37	2,596	68,457	30,970	Aug 05 06:40 PM
Drappa Jorn	Chief Medical Officer	Aug 03 '26	Sale	26.37	2,447	64,527	56,892	Aug 05 06:36 PM
Bradley Mark Christopher	Chief Development Officer	Aug 03 '26	Sale	26.37	2,572	67,824	48,533	Aug 05 06:21 PM
Pangali Sanam	Chief Legal Officer	Jul 06 '26	Option Exercise	5.06	5,000	25,300	16,111	Jul 08 04:40 PM
Pangali Sanam	Chief Legal Officer	Jul 06 '26	Sale	28.00	5,000	140,000	11,111	Jul 08 04:40 PM
SANAMPREET PANGALI	Officer	Jul 06 '26	Proposed Sale	28.00	5,000	140,000		Jul 06 04:06 PM
Drappa Jorn	Chief Medical Officer	May 22 '26	Option Exercise	6.65	26,852	178,649	59,339	May 27 07:06 PM
AKKARAJU SRINIVAS	Director	Jan 09 '26	Buy	17.00	588,235	9,999,995	1,853,488	Jan 13 06:20 PM
Foresite Labs, LLC	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:59 PM
Foresite Capital Management VI	10% Owner	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
Tananbaum James B.	Director	Jan 08 '26	Buy	17.00	411,764	6,999,988	5,702,536	Jan 12 09:58 PM
AKKARAJU SRINIVAS	Director	Dec 05 '25	Buy	9.84	186,377	1,833,760	1,265,253	Dec 09 07:13 PM
AKKARAJU SRINIVAS	Director	Dec 03 '25	Buy	7.75	100,000	775,000	1,012,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 02 '25	Buy	7.55	96,000	724,800	912,849	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 04 '25	Buy	8.18	66,027	540,101	1,078,876	Dec 04 08:11 PM
AKKARAJU SRINIVAS	Director	Dec 01 '25	Buy	7.46	86,350	644,171	816,849	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 26 '25	Buy	7.64	48,537	370,823	691,797	Dec 01 06:09 PM
AKKARAJU SRINIVAS	Director	Nov 28 '25	Buy	7.64	38,702	295,683	730,499	Dec 01 06:09 PM
Foresite Capital Management VI	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Tananbaum James B.	Director	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:02 PM
Foresite Labs, LLC	10% Owner	Nov 21 '25	Buy	7.38	72,212	532,925	2,614,215	Nov 25 04:01 PM
AKKARAJU SRINIVAS	Director	Nov 20 '25	Buy	7.20	125,743	905,350	643,260	Nov 24 06:50 PM
Foresite Labs, LLC	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:54 PM
Foresite Labs, LLC	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:54 PM
Foresite Capital Management VI	10% Owner	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:52 PM
Foresite Capital Management VI	10% Owner	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:52 PM
Tananbaum James B.	Director	Nov 19 '25	Buy	6.56	190,500	1,249,680	2,542,003	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 17 '25	Buy	5.59	200,000	1,118,500	2,234,129	Nov 19 08:51 PM
Tananbaum James B.	Director	Nov 18 '25	Buy	6.19	117,374	726,545	2,351,503	Nov 19 08:51 PM
AKKARAJU SRINIVAS	Director	Nov 19 '25	Buy	6.56	137,772	903,784	517,517	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 18 '25	Buy	6.05	102,652	621,045	379,745	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 17 '25	Buy	5.51	914	5,036	277,093	Nov 19 08:46 PM
AKKARAJU SRINIVAS	Director	Nov 13 '25	Buy	5.25	276,179	1,449,940	276,179	Nov 17 04:59 PM

LTGO

Latigo Biotherapeutics Inc

ALMS

Alumis Inc

Upgrade your Finviz experience